Cargando…

A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab

Immune checkpoint inhibitors are becoming of more use as clinicians are prescribing them for patients with different malignancies. As their use continues to increase, clinicians must be aware of the side effects, which are autoimmune in nature. Autoimmune diabetes has been described in the past whil...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazzi, Talal, Gupta, Eisha, Mohamed, Ayman, Vashi, Megha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595249/
https://www.ncbi.nlm.nih.gov/pubmed/36312693
http://dx.doi.org/10.7759/cureus.29537
_version_ 1784815604830568448
author Bazzi, Talal
Gupta, Eisha
Mohamed, Ayman
Vashi, Megha
author_facet Bazzi, Talal
Gupta, Eisha
Mohamed, Ayman
Vashi, Megha
author_sort Bazzi, Talal
collection PubMed
description Immune checkpoint inhibitors are becoming of more use as clinicians are prescribing them for patients with different malignancies. As their use continues to increase, clinicians must be aware of the side effects, which are autoimmune in nature. Autoimmune diabetes has been described in the past while patients were being treated with programmed cell death protein 1 (PD-1) inhibitors, but it usually occurs after the patient's fourth or fifth cycle. In this case presentation, we describe a patient with no history of type 1 or 2 diabetes presenting to the emergency department with severe diabetic ketoacidosis. At the time of presentation, he was on his 22nd cycle of nivolumab for metastatic renal cell carcinoma. The patient was eventually treated successfully, but upon discharge, he was prescribed a large dose of insulin regimen to control his blood sugar levels at home. We attributed his new diagnosis of insulin-dependent diabetes to the PD-1 inhibitor nivolumab.
format Online
Article
Text
id pubmed-9595249
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-95952492022-10-28 A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab Bazzi, Talal Gupta, Eisha Mohamed, Ayman Vashi, Megha Cureus Endocrinology/Diabetes/Metabolism Immune checkpoint inhibitors are becoming of more use as clinicians are prescribing them for patients with different malignancies. As their use continues to increase, clinicians must be aware of the side effects, which are autoimmune in nature. Autoimmune diabetes has been described in the past while patients were being treated with programmed cell death protein 1 (PD-1) inhibitors, but it usually occurs after the patient's fourth or fifth cycle. In this case presentation, we describe a patient with no history of type 1 or 2 diabetes presenting to the emergency department with severe diabetic ketoacidosis. At the time of presentation, he was on his 22nd cycle of nivolumab for metastatic renal cell carcinoma. The patient was eventually treated successfully, but upon discharge, he was prescribed a large dose of insulin regimen to control his blood sugar levels at home. We attributed his new diagnosis of insulin-dependent diabetes to the PD-1 inhibitor nivolumab. Cureus 2022-09-24 /pmc/articles/PMC9595249/ /pubmed/36312693 http://dx.doi.org/10.7759/cureus.29537 Text en Copyright © 2022, Bazzi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Bazzi, Talal
Gupta, Eisha
Mohamed, Ayman
Vashi, Megha
A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
title A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
title_full A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
title_fullStr A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
title_full_unstemmed A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
title_short A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
title_sort rare case of severe diabetic ketoacidosis in a patient with metastatic renal cell carcinoma being treated with nivolumab
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595249/
https://www.ncbi.nlm.nih.gov/pubmed/36312693
http://dx.doi.org/10.7759/cureus.29537
work_keys_str_mv AT bazzitalal ararecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab
AT guptaeisha ararecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab
AT mohamedayman ararecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab
AT vashimegha ararecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab
AT bazzitalal rarecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab
AT guptaeisha rarecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab
AT mohamedayman rarecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab
AT vashimegha rarecaseofseverediabeticketoacidosisinapatientwithmetastaticrenalcellcarcinomabeingtreatedwithnivolumab